MNG69
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.444
- OXIDATIVE_PHOSPHORYLATION+0.427
- MTORC1_SIGNALING+0.318
- E2F_TARGETS+0.310
- CHOLESTEROL_HOMEOSTASIS+0.306
- UNFOLDED_PROTEIN_RESPONSE+0.289
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.222
- FATTY_ACID_METABOLISM+0.219
- PROTEIN_SECRETION+0.217
- G2M_CHECKPOINT+0.212
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.409
- APICAL_SURFACE-0.370
- ANGIOGENESIS-0.358
- HEDGEHOG_SIGNALING-0.335
- INTERFERON_ALPHA_RESPONSE-0.308
- INTERFERON_GAMMA_RESPONSE-0.290
- MITOTIC_SPINDLE-0.288
- KRAS_SIGNALING_DN-0.286
- INFLAMMATORY_RESPONSE-0.272
- IL6_JAK_STAT3_SIGNALING-0.242
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 518420d3-dfdf-4163-99a4-2b8d7a04056c | — | — | 0.900 |
| 2 | debb199a-24be-4e87-84ea-2df67673457a | — | — | 0.869 |
| 3 | 054d5602-4089-4f34-a667-14c8edbb4167 | — | — | 0.864 |
| 4 | TCGA-34-5240-01A-01R-1443-07 | — | cohortSQ2 | 0.862 |
| 5 | SRR6013568 | — | cohortA2 | 0.847 |
| 6 | dfb9c45f-cb52-4e36-b663-1a9e8c7c0b47 | — | — | 0.845 |
| 7 | 4e2a5058-c190-49de-97f4-0ba7be7ebfe8 | — | — | 0.843 |
| 8 | 45a758dc-af09-48d3-8cd2-15232593f385 | — | — | 0.841 |
| 9 | SRR8518448 | — | C | 0.829 |
| 10 | DRR168541 | — | — | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.444 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.427 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.318 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.306 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.289 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.222 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.219 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.217 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.212 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.185 | Cobimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.179 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.176 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.171 | Inavolisib | — uncovered |
| PEROXISOME | 0.165 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.153 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.153 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.068 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.048 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.011 | Inavolisib | — uncovered |